The U.S. Food and Drug Administration recently gave the go-ahead to two new drugs, Xeljanz and Quillivant XR, to treat rheumatoid arthritis and Attention Deficit Hyperactivity Disorder, respectively, the manufacturing companies announced in separate statements.
The U.S. Small Business Administration is seeking nominations for awards honoring the critical economic role small businesses play in federally funded research and development through SBA’s Small Business Innovation Research (SBIR) and Small Business Technology ...
Praxair Inc. and its divisions and subsidiaries — Praxair Distribution, Inc., Praxair Healthcare Services, Praxair Canada Inc., and Praxair Puerto Rico B.V. — will be increasing the prices charged to its bulk and packaged, industrial, ...
